[1] Dailey ME, Lindsay S, Skahen R.  Relation of thyroid neoplasms to Hashimoto's disease of the thyroid gland[J]. AMA Arch Surg, 1955, 70(2): 291-297.   doi: 10.1001/archsurg.1955.01270080137023
[2] Liang J, Zeng W, Fang F, et al.  Clinical analysis of Hashimoto thyroiditis coexistent with papillary thyroid cancer in 1392 patients[J]. Acta Otorhinolaryngol Ital, 2017, 37(5): 393-400.   doi: 10.14639/0392-100X-1709
[3]

Zhang Y, Ma XP, Deng FS, et al. The effect of chronic lymphocytic thyroiditis on patients with thyroid cancer[J/OL]. World J Surg Oncol, 2014, 12: 277[2019-07-30]. https://wjso.biomedcentral.com/articles/10.1186/1477-7819-12-277. DOI: 10.1186/1477-7819-12-277.
[4]

Lai XJ, Xia Y, Zhang B, et al. A meta-analysis of Hashimoto's thyroiditis and papillary thyroid carcinoma risk[J/OL]. Oncotarget, 2017, 8(37): 62414−62424[2019-07-30]. https://www.oncotarget.com/article/18620/text. DOI: 10.18632/oncotarget.18620.
[5] Moon S, Chung HS, Yu JM, et al.  Associations between Hashimoto thyroiditis and clinical outcomes of papillary thyroid cancer: a meta-analysis of observational studies[J]. Endocrinol Metab (Seoul), 2018, 33(4): 473-484.   doi: 10.3803/EnM.2018.33.4.473
[6] Lee JH, Kim Y, Choi JW, et al.  The association between papillary thyroid carcinoma and histologically proven Hashimoto's thyroiditis: a meta-analysis[J]. Eur J Endocrinol, 2013, 168(3): 343-349.   doi: 10.1530/EJE-12-0903
[7] Uhliarova B, Hajtman A.  Hashimoto's thyroiditis-an independent risk factor for papillary carcinoma[J]. Braz J Otorhinolaryngol, 2018, 84(6): 729-735.   doi: 10.1016/j.bjorl.2017.08.012
[8] Ehlers M, Schott M.  Hashimoto's thyroiditis and papillary thyroid cancer: are they immunologically linked?[J]. Trends Endocrinol Metab, 2014, 25(12): 656-664.   doi: 10.1016/j.tem.2014.09.001
[9] Jankovic B, Le KT, Hershman JM.  Hashimoto's thyroiditis and papillary thyroid carcinoma: is there a correlation?[J]. J Clin Endocrinol Metab, 2013, 98(2): 474-482.   doi: 10.1210/jc.2012-2978
[10] Nemetz MA, Thomazelli FC, Granero LC, et al.  Does chronic lymphocytic thyroiditis influence the staging of differentiated thyroid carcinoma?[J]. Braz J Otorhinolaryngol, 2011, 77(1): 77-83.   doi: 10.1590/S1808-86942011000100013
[11]

葛华. 甲状腺自身免疫异常的DTC患者131I治疗效果及预后的研究[D]. 福州: 福建医科大学, 2016.

Ge H. The 131I radiotherapy effect and prognosis of DTC complicated by abnormal thyroid autoimmunity[D]. Fuzhou: Fujian Medical University, 2016.
[12]

陈艳林. Tg对甲状腺自身免疫异常的DTC患者预后监测的价值[D]. 郑州: 郑州大学, 2013.

Chen YL. The value of serum Tg in the prognosis of differentiated thyroid cancer with abnormal thyroid autoimmunity[D]. Zhengzhou: Zhengzhou University, 2013.
[13] Xing MZ, Alzahrani AS, Carson KA, et al.  Association between BRAFV600E mutation and recurrence of papillary thyroid cancer[J]. J Clin Oncol, 2015, 33(1): 42-50.   doi: 10.1200/JCO.2014.56.8253
[14] Zhang Q, Liu SZ, Zhang Q, et al.  Meta-analyses of association between BRAFV600E mutation and clinicopathological features of papillary thyroid carcinoma[J]. Cell Physiol Biochem, 2016, 38(2): 763-776.   doi: 10.1159/000443032
[15] Repplinger D, Bargren A, Zhang YW, et al.  Is Hashimoto's thyroiditis a risk factor for papillary thyroid cancer?[J]. J Surg Res, 2008, 150(1): 49-52.   doi: 10.1016/j.jss.2007.09.020
[16] 章幂, 章佳新, 冯倩倩.  桥本甲状腺炎合并甲状腺乳头状癌组织中survivin和Ki-67的表达变化及意义[J]. 山东医药, 2015, 55(24): 64-66.   doi: 10.3969/j.issn.1002-266X.2015.24.028
Zhang M, Zhang JX, Feng QQ.  Expression and significance of survivin and Ki-67 in Hashimoto's thyroiditis with papillary thyroid carcinoma[J]. Shandong Med J, 2015, 55(24): 64-66.   doi: 10.3969/j.issn.1002-266X.2015.24.028
[17] 李晓梅, 侯刚.  CK19、COX-2、hTERT在桥本甲状腺炎合并甲状腺乳头状癌中的表达及意义[J]. 临床与实验病理学杂志, 2010, 26(5): 619-622.   doi: 10.3969/j.issn.1001-7399.2010.05.029
Li XM, Hou G.  The expression and significance of CK19, COX-2 and hTERT in Hashimoto's thyroiditis complicated with papillary thyroid carcinoma[J]. Chin J Clin Exp Pathol, 2010, 26(5): 619-622.   doi: 10.3969/j.issn.1001-7399.2010.05.029
[18] Kim HS, Choi YJ, Yun JS.  Features of papillary thyroid microcarcinoma in the presence and absence of lymphocytic thyroiditis[J]. Endocr Pathol, 2010, 21(3): 149-153.   doi: 10.1007/s12022-010-9124-9
[19] 代妮娜, 刘燕娜, 郭良云, 等.  超声对桥本氏甲状腺炎合并甲状腺癌的诊断价值[J]. 江西医药, 2015, 50(1): 78-80.   doi: 10.3969/j.issn.1006-2238.2015.01.036
Dai NN, Liu YN, Guo LY, et al.  Diagnostic value of ultrasonography in Hashimoto's thyroiditis with thyroid cancer[J]. Jiangxi Med J, 2015, 50(1): 78-80.   doi: 10.3969/j.issn.1006-2238.2015.01.036
[20] 张琼, 王兴田.  常规超声联合弹性成像应变率比值法对桥本氏甲状腺炎合并甲状腺癌的最佳诊断临界点及其诊断价值[J]. 实用癌症杂志, 2017, 32(11): 1886-1889.   doi: 10.3969/j.issn.1001-5930.2017.11.043
Zhang Q, Wang XT.  Optimal diagnostic critical point of conventional ultrasound combined with elastography strain ratio method for the didgnosis of Hashimoto's thyroiditis with thyroid cancer and it diagnostic value[J]. Pract J Cancer, 2017, 32(11): 1886-1889.   doi: 10.3969/j.issn.1001-5930.2017.11.043
[21] Sakorafas GH.  Thyroid nodules; interpretation and importance of fine-needle aspiration (FNA) for the clinician-practical considerations[J]. Surg Oncol, 2010, 19(4): e130-e139.   doi: 10.1016/j.suronc.2010.06.003
[22] 蓝小春.  桥本甲状腺炎38例临床分析[J]. 现代实用医学, 2017, 29(3): 336-337.   doi: 10.3969/j.issn.1671-0800.2017.03.027
Lan XC.  Clinical analysis of 38 cases of Hashimoto's thyroiditis[J]. Mod Pract Med, 2017, 29(3): 336-337.   doi: 10.3969/j.issn.1671-0800.2017.03.027
[23] Haigh PI, Urbach DR, Rotstein LE.  Extent of thyroidectomy is not a major determinant of survival in low- or high-risk papillary thyroid cancer[J]. Ann Surg Oncol, 2005, 12(1): 81-89.   doi: 10.1007/s10434-004-1165-1
[24] 龚卫东, 黄堃, 王南鹏.  桥本甲状腺炎合并甲状腺癌的诊断与治疗[J]. 中国普外基础与临床杂志, 2013, 20(6): 643-647.   doi: 10.7507/1007-9424.20130168
Gong WD, Huang K, Wang NP.  Diagnosis and treatment of Hashimoto thyroiditis coexistense with thyroid cancer[J]. Chin J Bases Clin General Surg, 2013, 20(6): 643-647.   doi: 10.7507/1007-9424.20130168
[25] 李娇, 梁军, 杨涛, 等.  伴桥本甲状腺炎的甲状腺乳头状癌患者131I清除残留甲状腺疗效评价[J]. 中华核医学与分子影像杂志, 2016, 36(6): 481-485.   doi: 10.3760/cma.j.issn.2095-2848.2016.06.001
Li J, Liang J, Yang T, et al.  Outcome of radioiodine therapy in patients with papillary thyroid carcinoma concurrent with Hashimoto's thyroiditis[J]. Chin J Nucl Med Mol Imaging, 2016, 36(6): 481-485.   doi: 10.3760/cma.j.issn.2095-2848.2016.06.001
[26] Kwon H, Choi JY, Moon JH, et a1.  Effect of Hashimoto thyroiditis on low-dose radioactive-iodine remnant ablation[J]. Head Neck, 2016, 38(Suppl 1): S730-735.   doi: 10.1002/hed.24080
[27] 张腾, 胡厚洋, 柏庆花, 等.  慢性淋巴细胞性甲状腺炎对分化型甲状腺癌放射性碘清甲治疗效果的影响[J]. 中国癌症杂志, 2018, 28(6): 419-423.   doi: 10.19401/j.cnki.1007-3639.2018.06.004
Zhang T, Hu HY, Bai QH, et al.  Effect of lymphocytic thyroiditis on response of differentiated thyroid cancer patients after 131I therapy[J]. China Oncol, 2018, 28(6): 419-423.   doi: 10.19401/j.cnki.1007-3639.2018.06.004